Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
Go back to Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity| Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) | Delayed: 59.17 +0.06 (0.10%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.11 | 52 Week High | $35.13 | |||
| Open | $58.65 | 52 Week Low | $28.10 | |||
| Day High | $59.36 | P/E | N/A | |||
| Day Low | $58.41 | EPS | $0.00 | |||
| Volume | 397,187 | |||||



